First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

MLA

Manish R. Patel, et al. “First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-Positive Advanced Breast or Gastric Cancer.” Molecular Cancer Therapeutics, vol. 20, May 2021, pp. 1442–53. EBSCOhost, https://doi.org/10.1158/1535-7163.mct-20-0014.

APA

Manish R. Patel, Peng He, Antoinette R. Tan, Anita Scheuber, Shannon Marshall, Anton I. Rosenbaum, Kemal Balic, Erika Hamilton, Mark D. Pegram, Mayukh Das, Meina Liang, & Anna Maria Storniolo. (2021). First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Molecular Cancer Therapeutics, 20, 1442–1453. https://doi.org/10.1158/1535-7163.mct-20-0014

Chicago

Manish R. Patel, Peng He, Antoinette R. Tan, Anita Scheuber, Shannon Marshall, Anton I. Rosenbaum, Kemal Balic, et al. 2021. “First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-Positive Advanced Breast or Gastric Cancer.” Molecular Cancer Therapeutics 20 (May): 1442–53. doi:10.1158/1535-7163.mct-20-0014.